Loss of CD55 Is Associated with Aggressive Breast Tumors
- 15 April 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (8) , 2797-2803
Abstract
Purpose: CD55 is a complement regulatory protein expressed by cells to protect them from bystander attack by complement. CD55 is overexpressed on some tumor cell lines, and in colorectal carcinomas, it has been shown to be an indicator of poor prognostic. Experimental Design: A large set of samples (480) from patients with primary operable breast cancer followed for 4–192 months were included in the present study. The prognostic significance of CD55 was then investigated in these tumors using an anti-CD55 monoclonal antibody (RM1) that we raised against a synthetic peptide and a standard immunohistochemistry method. Results: Ninety-five percent of the breast carcinomas expressed CD55 (RM1) with intensity ranging from weak (51%) to strong (6%). High expression of CD55 was significantly associated with low-grade (grades 1 or 2; P = 0.001), lymph node negativity (P = 0.031), and good prognosis tumors (Nottingham Prognostic Index < 3.4; P < 0.001). Survival analysis showed CD55 overexpression was associated with a more favorable outcome and loss of CD55 being associated with poor survival (P = 0.001). Intensity of CD55 expression was significantly correlated (P = 0.002) with intensity of CD59 expression (as shown in a previous study) in these series of patients. Conclusions: In conclusion, we found that loss of both CD55 and CD59 in breast carcinomas is associated with a worse prognosis.Keywords
This publication has 22 references indexed in Scilit:
- Loss of CD59 expression in breast tumours correlates with poor survivalThe Journal of Pathology, 2003
- The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissuesAPMIS, 1998
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: A preventive mechanism of malignant tumor cells against complement attack?Breast Cancer Research and Treatment, 1994
- The Nottingham prognostic index in primary breast cancerBreast Cancer Research and Treatment, 1992
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991
- Biology of complement: the overtureImmunology Today, 1991
- Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46).Journal of Experimental Medicine, 1990
- Decay‐accelerating Factor (DAF): A Review of its Function and StructureActa Medica Scandinavica, 1987
- Antibodies to major histocompatibility antigens produced by hybrid cell linesNature, 1977